Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Martin Lagging

Professor/överläkare

Martin Lagging
Professor/överläkare
Specialistläkare i infektionssjukdomar och virologi
Akademisk grad: Docent,
martin.lagging@medfak.gu.se
0 31-342 4731
0705-683759

Rumsnummer: Våning 5
Postadress: Guldhedsgatan 10A, 41346 Göteborg
Besöksadress: Guldhedsgatan 10A , 41346 Göteborg
Arbetsuppgifter: Professor, universitetssjukhusöverläkare


Avd för infektionssjukdomar vid Institutionen för biomedicin (Mer information)
Box 440
405 30 Göteborg
0313421000
Fax: 0 31846113

Besöksadress: Medicinaregatan 3, plan 5 , 405 30 Göteborg

Om Martin Lagging

Role of Genetic Variations of Innate Immunity in Microbial Infections

Research Focus:

Our group has focused on translational studies and interventional/therapeutic trials on hepatitis C virus (HCV) with the goal of improving outcome as well as minimizing the risk of adverse events. In particular, we evaluated the impact of host factors such as interferon-gamma inducible protein 10 (IP-10; also known as CXCL10) as well human genetic variants, e.g. in the gene coding for interferon-lambda 4 (IFNL4; previously known as IL28B), on liver histopathology, response to therapy, and outcome for HCV treatment.

More recently, we have evaluated the impact of genetic variations in the inosine triphosphate pyrophosphatase (ITPase) gene on HCV infection, and reported a novel ribavirin-like reduced risk of relapse among patients having reduced ITPase activity. The evolutionary conserved ITPase is a cytosolic enzyme that recycles purines by the pyrophosphohydrolysis of ITP to inosine monophosphate (IMP), and thus protects against accumulation of non-canonical nucleotides such as ITP and xanthosine triphosphate (XTP) as well as their deoxy forms (dITP and dXTP), which otherwise incorrectly may be incorporated into RNA and DNA producing genetic instability, anomalous proteins, and altered ATP-dependent signaling.

In the near future, we plan to expand our evaluation of ITPase to include other microbial infections, as we hypothesize that inhibition of ITPase may point to novel antiviral and antibacterial strategies.

Senaste publikationer

Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study
O. Dalgard, O. Weiland, G. Noraberg, L. Karlsen, L. Heggelund et al.
Plos One, Artikel i vetenskaplig tidskrift 2017
Artikel i vetenskaplig tidskrift

Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016.
Martin Lagging, Rune Wejstål, Gunnar Norkrans, Olle Karlström, Soo Aleman et al.
Infectious diseases (London, England), Artikel i vetenskaplig tidskrift 2017
Artikel i vetenskaplig tidskrift

High seroprevalence against hepatitis E virus in patients with chronic hepatitis C virus infection
A. Mellgren, M. Karlsson, Marie Karlsson, Martin Lagging, Rune Wejstål et al.
Journal of Clinical Virology, Artikel i vetenskaplig tidskrift 2017
Artikel i vetenskaplig tidskrift

Prevalence and comorbidities of chronic hepatitis C: a nationwide population-based register study in Sweden
K. Busch, Jesper Waldenström, Martin Lagging, S. Aleman, O. Weiland et al.
Scandinavian Journal of Gastroenterology, Artikel i vetenskaplig tidskrift 2017
Artikel i vetenskaplig tidskrift

Imported case of lassa fever in Sweden with encephalopathy and sensorineural hearing deficit
Anna Grahn, Andreas Bråve, Martin Lagging, Leif Dotevall, David Ekqvist et al.
Open Forum Infectious Diseases, Artikel i vetenskaplig tidskrift 2016
Artikel i vetenskaplig tidskrift

Diagnostic Performance of Five Assays for Anti-Hepatitis E Virus IgG and IgM in a Large Cohort Study.
Helene Norder, Marie Karlsson, Åsa Mellgren, Jan Konar, Elisabeth Sandberg et al.
Journal of clinical microbiology, Artikel i vetenskaplig tidskrift 2016
Artikel i vetenskaplig tidskrift

Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial
Martin Lagging, A. Brown, P. S. Mantry, A. Ramji, F. Weilert et al.
Journal of Viral Hepatitis, Artikel i vetenskaplig tidskrift 2016
Artikel i vetenskaplig tidskrift

Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience
Jesper Waldenström, M. Farkkila, Karolina Rembeck, Gunnar Norkrans, N. Langeland et al.
Scandinavian Journal of Gastroenterology, Artikel i vetenskaplig tidskrift 2016
Artikel i vetenskaplig tidskrift

Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations.
Martin Lagging, Rune Wejstål, Gunnar Norkrans, Olle Karlström, Soo Aleman et al.
Infectious diseases (London, England), Artikel i övriga tidskrifter 2015
Artikel i övriga tidskrifter

Visar 1 - 10 av 70

2017

Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study
O. Dalgard, O. Weiland, G. Noraberg, L. Karlsen, L. Heggelund et al.
Plos One, Artikel i vetenskaplig tidskrift 2017
Artikel i vetenskaplig tidskrift

Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016.
Martin Lagging, Rune Wejstål, Gunnar Norkrans, Olle Karlström, Soo Aleman et al.
Infectious diseases (London, England), Artikel i vetenskaplig tidskrift 2017
Artikel i vetenskaplig tidskrift

High seroprevalence against hepatitis E virus in patients with chronic hepatitis C virus infection
A. Mellgren, M. Karlsson, Marie Karlsson, Martin Lagging, Rune Wejstål et al.
Journal of Clinical Virology, Artikel i vetenskaplig tidskrift 2017
Artikel i vetenskaplig tidskrift

Prevalence and comorbidities of chronic hepatitis C: a nationwide population-based register study in Sweden
K. Busch, Jesper Waldenström, Martin Lagging, S. Aleman, O. Weiland et al.
Scandinavian Journal of Gastroenterology, Artikel i vetenskaplig tidskrift 2017
Artikel i vetenskaplig tidskrift

2016

Imported case of lassa fever in Sweden with encephalopathy and sensorineural hearing deficit
Anna Grahn, Andreas Bråve, Martin Lagging, Leif Dotevall, David Ekqvist et al.
Open Forum Infectious Diseases, Artikel i vetenskaplig tidskrift 2016
Artikel i vetenskaplig tidskrift

Diagnostic Performance of Five Assays for Anti-Hepatitis E Virus IgG and IgM in a Large Cohort Study.
Helene Norder, Marie Karlsson, Åsa Mellgren, Jan Konar, Elisabeth Sandberg et al.
Journal of clinical microbiology, Artikel i vetenskaplig tidskrift 2016
Artikel i vetenskaplig tidskrift

Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial
Martin Lagging, A. Brown, P. S. Mantry, A. Ramji, F. Weilert et al.
Journal of Viral Hepatitis, Artikel i vetenskaplig tidskrift 2016
Artikel i vetenskaplig tidskrift

Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience
Jesper Waldenström, M. Farkkila, Karolina Rembeck, Gunnar Norkrans, N. Langeland et al.
Scandinavian Journal of Gastroenterology, Artikel i vetenskaplig tidskrift 2016
Artikel i vetenskaplig tidskrift

2015

Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations.
Martin Lagging, Rune Wejstål, Gunnar Norkrans, Olle Karlström, Soo Aleman et al.
Infectious diseases (London, England), Artikel i övriga tidskrifter 2015
Artikel i övriga tidskrifter

Visar 1 - 10 av 70

Sidansvarig: Cecilia Koskinen|Sidan uppdaterades: 2017-08-28
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?